5 completed, 4 recruiting, 3 active not recruiting, 2 unknown. 11 Phase 2, 4 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Active not recruiting 3, Recruiting 3, Unknown 1 |
| Phase 1 | 4 | Active not recruiting 3, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
Follow Pemetrexed (Alimta): new trials by email Literature Review of Pemetrexed (Alimta) trials Research Report on Pemetrexed (Alimta)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Cemiplimab, Fianlimab, Pemetrexed (Alimta) - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 126 | 2026-04-02 | 2026-08-11 |
| Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated Tepotinib, Pemetrexed (Alimta), Vinorelbine - Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 133 | 2025-12-09 | 2025-12-17 |
| Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer MaaT033 capsule, Cemiplimab, Cisplatin - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 162 | 2025-11-17 | 2026-04-03 |
| Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis AK112, Pemetrexed (Alimta) - Leptomeningeal Metastasis, Intrathecal Drug Delivery | Phase 1 / Phase 2 | Recruiting | Guangzhou Medical University | 34 | 2025-03-18 | 2025-05-20 |
| Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta) - Leptomeningeal Metastasis, Pemetrexed | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-17 | 2026-10-13 |
| Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis Cadonilimab (AK104), Pemetrexed (Alimta) - Leptomeningeal Metastasis | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-07 | 2026-10-13 |
| A Phase 1/2 Study of BA3071 in Patients With Solid Tumors BA3071, Nivolumab, Pembrolizumab - NSCLC, Melanoma | Phase 1 / Phase 2 | Active not recruiting | BioAtla, Inc. | 320 | 2022-08-03 | 2025-06-15 |
| Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy combined group, Sequenced group - Non Small Cell Lung Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2012-10-01 | 2012-12-10 |
| Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma Neoadjuvant Bevacizumab - Lung Cancer | Phase 2 | Completed | Si-Yu Wang | 42 | 2012-04-01 | 2015-01-22 |
| Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). bevacizumab, erlotinib, bevacizumab, pemetrexed, cisplatin - Lung Cancer | Phase 2 | Completed | Swiss Cancer Institute | 149 | 2010-06-01 | 2019-05-15 |
| Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma erlotinib (Tarceva), pemetrexed (Alimta) - Non-Small Cell Lung Cancer | Not applicable | Unknown | National Cheng-Kung University Hospital | 52 | 2009-03-01 | 2009-05-18 |
| Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations Pemetrexed (Alimta), Gefitinib (IRESSA) - Non Small Cell Lung Cancer | Phase 2 | Completed | Chinese Society of Lung Cancer | 161 | 2009-02-01 | 2012-12-10 |
| Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy Pemetrexed (Alimta) - Nasopharyngeal Neoplasms | Phase 2 | Completed | Sun Yat-sen University | 35 | 2007-11-01 | 2012-02-16 |
| Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC) Erlotinib (Tarceva), Pemetrexed (Alimta) - Non Small Cell Lung Cancer | Phase 3 | Completed | Hellenic Oncology Research Group | 320 | 2006-04-01 | 2010-08-19 |
Carcinoma, Non-Small-Cell Lung (7) · Meningeal Carcinomatosis (3) · Adenocarcinoma of Lung (2) · Lung Neoplasms (2) · Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Nasopharyngeal Neoplasms (1) · Neoplasm Metastasis (1)
Guangzhou Medical University (3) · Intergroupe Francophone de Cancerologie Thoracique (2) · BioAtla, Inc. (1) · Chinese Society of Lung Cancer (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hellenic Oncology Research Group (1) · National Cheng-Kung University Hospital (1) · Peking Union Medical College Hospital (1) · Si-Yu Wang (1) · Sun Yat-sen University (1) · Swiss Cancer Institute (1)
China (7) · France (3) · Australia (1) · Greece (1) · Switzerland (1) · Taiwan (1) · United States (1)
Zhenyu Pan, PhD,MD (2) · Adrian Ochsenbein, MD (1) · Athanasios Karampeazis, MD (1) · Lampros Vamvakas, MD (1) · Li Zhang, Master (1) · Mengzhao Wang, MD (1) · Nicolas Mach, MD (1) · Oliver Gautschi, MD (1) · Sacha Rothschild, MD (1) · Si-Yu Wang, Doctor (1) · Wu-Chou Su, PhD (1) · Zhenyu Pan, PhD, MD (1)
PMID 21194487, PMID 21784628, PMID 22237124, PMID 22333554, PMID 25281710, PMID 27993482